Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation.

摘要

Post-essential thrombocythemia myelofibrosis (post-ET MF) may occur as a late event during the course of ET. Criteria for diagnosis of post-ET MF have been recently established by the International Working Group on Myelofibrosis Research and Treatment. Once ET evolves into post-ET MF, survival is worsened, and in a few instances hemopoietic allo-SCT may be considered as a treatment option. Patients with myelofibrosis may carry the JAK2 (V617F) mutation or, more rarely, mutations within the MPL gene. This allows one to study minimal residual disease after allo-SCT by monitoring these activating molecular mutations in positive patients.